In preclinical models of GBM, CAR-T cells have demonstrated robust antitumor activity and are currently being evaluated in phase I/II studies targeting glioma-specific, antigens IL-13Rα2, HER2, and EGFR. The gene discussed is ERBB2; the disease is glioma.